Speak to a healthcare professional promptly if you notice: blurry vision dark spots in your field of vision floaters sudden loss of vision flashing lights changes in how you see colour If you ever experience changes to your eyesight, it is important not to ignore them
Both GLP-1 (7-36) and GLP-1 (7-37) also play roles in gastric motility (gastric emptying), on the suppression of plasma glucagon levels (glucose production) and possibly on the promotion of satiety and stimulation of glucose disposal in peripheral tissues independent of the actions of insulin
Similar results were reported by Wang et al., where GLP-1 RA treatment had a notable impact on the abundance of weight-related microbial phylotypes, though no significant change in the Firmicutes/Bacteroidetes ratio was observed (72)
Retatrutide is designed to activate these three receptors in a way that affects appetite, fullness, glucose control and metabolism
When activated, these receptors trigger several beneficial effects: Enhanced insulin secretion The pancreas releases insulin in response to elevated blood glucose levels, but only when needed (glucose-dependent mechanism) Reduced glucagon release Glucagon, which raises blood sugar, is suppressed when glucose levels are adequate Delayed gastric emptying Food moves more slowly from the stomach into the intestines, promoting satiety Appetite regulation Signals to the brain's appetite centres reduce hunger and food intake Unlike naturally occurring GLP-1, which is rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4) within minutes, pharmaceutical GLP-1 receptor agonists are chemically modified to resist this degradation